Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02471274 · ClinicalTrials.gov registry record · Phase 1
PK Study of Sotagliflozin in Subjects With Hepatic Impairment
A Phase 1 study, sponsored by Lexicon Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
NCT02471274 is a Phase 1 study that has completed, run by Lexicon Pharmaceuticals. The registered enrollment target is 32 participants.
The verdict
NCT02471274, a Phase 1 study, has completed, sponsored by Lexicon Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
Study Summary
To evaluate the effect of mild, moderate, or severe hepatic impairment on the pharmacokinetics (PK) of a single dose of 400 mg sotagliflozin (2 x 200-mg tablets) compared with healthy, demographically-matched subjects.
Interventions
- DRUG sotagliflozin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2015-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02471274
The ClinicalTrials.gov registry entry for NCT02471274 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Lexicon Pharmaceuticals, which has 56 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which sotagliflozin is the first listed.
NCT02471274 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02471274 about?
NCT02471274 is a clinical study titled "PK Study of Sotagliflozin in Subjects With Hepatic Impairment". To evaluate the effect of mild, moderate, or severe hepatic impairment on the pharmacokinetics (PK) of a single dose of 400 mg sotagliflozin (2 x 200-mg tablets) compared with healthy, demographically-matched subjects.
What is the current status of trial NCT02471274?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2015-06.
What interventions are being tested in trial NCT02471274?
The interventions under investigation include: sotagliflozin (DRUG).
Who is sponsoring clinical trial NCT02471274?
This trial is sponsored by Lexicon Pharmaceuticals, which has 56 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.